Antibodies, Bispecific

NEW ORLEANS — In this video perspective, Nikhil C. Munshi, MD, discusses presentations from the ASH Annual Meeting and Exposition that focus on advances in bispecific antibody treatments for patients with multiple myeloma.

In the 24 patients with relapsed or refractory multiple myeloma who received the phase 2 recommended dose of talquetamab, the overall response rate was 70%, according to phase 1 data presented at the virtual ASCO Annual Meeting.